This inventor holds 7 USPTO granted patents and 3 published patent applications, plus 4 CIPO patents and 3 EPO patents. Top assignees: Disruptive Materials Ab, Disruptive Materials Operations Ab, Nvigorea Ab. Active years: 2014-2022.
Company Filing History:
2 out of 2 
1 out of 2 
1 out of 1 Years Active: 2014-2022
Title: Albert Mihranyan: Innovator in Pharmaceutical Formulations
Introduction
Albert Mihranyan is a notable inventor based in Uppsala, Sweden. He has made significant contributions to the field of pharmaceutical formulations, holding a total of 7 patents. His work focuses on improving drug delivery systems, particularly for poorly soluble active ingredients.
Latest Patents
One of Mihranyan's latest patents is titled "Rapid release pharmaceutical formulations containing algal cellulose." This invention provides a pharmaceutical composition that includes cellulose derived from algae, or its derivatives, combined with an active pharmaceutical ingredient in a predominantly amorphous form. The formulations are particularly useful for BCS Type 2 and 4 drugs, including NSAIDs, which are employed in treating conditions such as migraine and dysmenorrhea. Another significant patent is for the "Preparation and use of cellulose nanofiber membrane." This invention describes a filtration membrane made from cellulose fibers, designed with a specific pore size distribution to enhance its filtration capabilities.
Career Highlights
Throughout his career, Mihranyan has worked with various companies, including Disruptive Materials AB. His innovative approaches have led to advancements in pharmaceutical technology, making a positive impact on drug formulation and delivery.
Collaborations
Mihranyan has collaborated with notable professionals in his field, including Maria Strömme and Johan Gómez De La Torre. These partnerships have contributed to the development of his groundbreaking inventions.
Conclusion
Albert Mihranyan's work exemplifies the importance of innovation in the pharmaceutical industry. His patents reflect a commitment to enhancing drug delivery systems, ultimately benefiting patients worldwide.